Abcam, ab265029, Human MBD1 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
MBD1 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MBD1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Methyl-CpG binding domain protein 1 (MBD1) also known as CXXC-type and BYE1 domain containing 1 recognizes and binds to methylated CpG sites in the DNA. This protein has a molecular weight of approximately 70 kDa. MBD1 is expressed widely in human tissues with higher levels detectable in the brain particularly the cerebral cortex. It acts within the nucleus where it functions as an important participant in the regulation of gene expression through DNA methylation.
Biological function summary
MBD1 influences the repression or activation of genomic transcription. It binds to methylated DNA and interacts with other proteins including methyl CpG binding proteins to form transcriptional repression complexes. This activity plays a role in gene silencing and modulation. MBD1 ensures proper interpretation of epigenetic marks therefore sustaining cellular identity and lineage commitment. In some cells MBD1 also engages with chromatin remodeling complexes to influence chromatin structure.
Pathways
MBD1 plays a significant role in the epigenetic and transcription regulation pathways. It is directly involved in DNA methylation processes interacting with histone deacetylases such as HDAC1 and other chromatin-modifying proteins. The pathway provides an important mechanism for long-term transcriptional silencing affecting developmental processes and cellular differentiation through methylation-dependent transcriptional regulation. MBD1 shares pathway interactions with proteins like MeCP2 highlighting interconnected roles in maintaining DNA methylation landscapes.
MBD1 has links to neurological disorders and cancer. It shows associations with Rett syndrome a neurodevelopmental disorder through its interaction with other methyl CpG binding proteins. Mutations or dysregulation in MBD1's function can disrupt normal methylation patterns contributing to gene expression changes seen in disease states. In cancer aberrant MBD1 expression may lead to inappropriate gene silencing impacting tumor suppressor genes. Many cancers including glioblastoma exhibit altered MBD1 expression levels implicating its role in tumorigenesis.